Table 1. Patient demographics.
| Variable | n (%)/value | Range (reference values and SI-unit) |
|---|---|---|
| Mean/median age | 71/71 | 53–86 (years) |
| ECOG | ||
| 0 | 13 (24.1) | |
| 1 | 22 (40.7) | |
| 2 | 17 (31.5) | |
| 3 | 2 (3.7) | |
| Bone metastasis | ||
| <6 | 10 (18.5) | |
| 6–20 | 16 (29.6) | |
| >20 | 21 (38.9) | |
| Super scan | 7 (13.0) | |
| Mean/median pre-therapeutic hematopoetic parameters | ||
| Hb start | 11.7/12.1 | 8.3–14.2 (13.5–18.0 g/dL) |
| Leuk start | 6.4/6.2 | 2.4–11.4 (4.0–10.0 G/L) |
| Plts start | 243.8/227.5 | 81.0–534.0 (150–350 G/L) |
| Mean/median post-therapeutic hematopoetic parameters | ||
| Hb end | 11.0/11.7 | 6.9–13.8 (13.5–18.0 g/dL) |
| Leuk end | 5.0/4.9 | 2.2–10.5 (4.0–10.0 G/L) |
| Plts end | 200.8/198.0 | 44.0–458 (150–350 G/L) |
| Previous treatments | ||
| RPE | 43 (79.6) | |
| CHT | 29 (53.7) | |
| Docetaxel + Cabazitaxel | 5 (9.3) | |
| RT | 39 (72.2) | |
| CHT + RT | 23 (42.6) | |
| Ongoing therapies | ||
| LHRH-Antagonist | 20 (37.0) | |
| Enzalutamid/Bicalutamid | 8 (14.8) | |
| Arbirateron | 4 (7.4) | |
| GnRH-Antagonist | 9 (16.7) | |
| None | 13 (24.1) |